FRI0296 Is There A Difference in the Effectiveness in the Treatment of Rheumatoid Arthritis with Rituximab in Patients with Rheumatoid Factor Positive and Negative? A Systematic Review

Published on Jun 1, 2014in Annals of the Rheumatic Diseases14.299
· DOI :10.1136/annrheumdis-2014-eular.4000
Alfredo Ortiz20
Estimated H-index: 20
M.P. Rosario Lozano1
Estimated H-index: 1
+ 1 AuthorsI. González-Άlvaro1
Estimated H-index: 1
Background Since the description of the efficacy of rituximab (RTX) in treating patients with rheumatoid arthritis (RA), the use of this drug has been extended. However it is not clearly established the patient profile in which the administration of RTX may show greater benefit. Objectives To systematically review the published evidence to date regarding on the difference in efficacy in the treatment of RA with RTX in patients with rheumatoid factor (RF) positive and negative. Methods A sensitive search of all published studies on the difference in the efficacy of RTX in RA patients with RF positive and negative was performed in Medline, Embase and Cochrane Central databases since its inception until July 2013. We selected all studies involving adult patients with RA seropositive for RF in which intervention was described as treatment with RTX and comparator as the administration of RTX to adult patients with RA seronegative for RF. Any standardized measure of efficacy in RA was considered as outcome measure. Although meta analysis, systematic reviews, clinical trials and cohorts well designed were preferably selected, finally we also included open studies and all studies that showed a methodologically correct subanalysis related to the question even if it had not been his main objective. After removing duplicates, an initial selection by reading titles, a second selection after reading abstracts and, finally, full reading of selected studies, assessing the methodological quality by levels of the Oxford Centre for Evidence Based Medicine Evidence (2001 update) where applicable, was carried out. A manual search of the references of included studies was also performed. Results A total of 362 citations about the treatment with RTX of RA patients seropositive and seronegative for RF were identified, which were reduced to 54 after removing duplicates and selection by reading titles and abstracts. Of the 54 selected articles, finally 36 were included in the review, one of which is a meta analysis that includes four of the clinical trials included in that review and their conclusions define de result of the same given the highest quality from the methodological point of view. The rest are 5 clinical trials, 7 prospective studies, 7 retrospective and 16 communications to Congresses or sub-analysis of previous studies. Conclusions RTX shows greater efficacy in the treatment of RA patients seropositive respect to seronegative, both in intensity and response rate (level of evidence 1a, grade of recommendation A). However, despite the level of evidence, due to the modest difference in efficacy between seropositive and seronegative patients and the results obtained after treatment with RTX in seronegative ones, it would be necessary the implementation of studies in this subgroup of patients to define the role of RTX in the treatment thereof. Acknowledgements This work has been funded by the Spanish Society of Rheumatology. Disclosure of Interest A. M. Ortiz Grant/research support: Spanish Society of Rheumatology, M. Rosario Lozano: None declared, C. Martinez Fernandez: None declared, I. Gonzalez-Άlvaro Grant/research support: Spanish Society of Rheumatology DOI 10.1136/annrheumdis-2014-eular.4000
  • References (0)
  • Citations (303)
📖 Papers frequently viewed together
1,171 Citations
16.2k Citations
896 Citations
78% of Scinapse members use related papers. After signing in, all features are FREE.
Cited By303
Primary biliary cholangitis (PBC) and primary sclerosing cholangitis (PSC) are autoimmune cholangiopathies characterized by limited treatment options. A more accurate understanding of the several pathways involved in these diseases has fostered the development of novel and promising targeted drugs. For PBC, the characterization of the role of farnesoid X receptor (FXR) and perixosome-proliferator activated receptor (PPAR) has paved the way to several clinical trials including different molecules...
#1Eric F. Morand (Monash University)H-Index: 50
#2David A. Isenberg (UCL: University College London)H-Index: 103
Last. Joan T. Merrill (OMRF: Oklahoma Medical Research Foundation)H-Index: 67
view all 9 authors...
OBJECTIVE: Low disease activity (LDA) and remission are emerging treat-to-target (T2T) endpoints in SLE. However, the rates at which these endpoints are met in patients with high disease activity (HDA) are unknown. Atacicept, which targets B lymphocyte stimulator and a proliferation-inducing ligand, improved disease outcomes in SLE patients with HDA (SLEDAI-2K >/=10) at baseline in the phase 2b ADDRESS II study. This is a post hoc analysis of T2T endpoints in these patients. METHODS: Patients re...
#1Jia-Feng Chen (CGU: Chang Gung University)H-Index: 3
#2Chung-Yuan Hsu (CGU: Chang Gung University)H-Index: 3
Last. Tien-Tsai Cheng (CGU: Chang Gung University)H-Index: 2
view all 9 authors...
OBJECTIVES: To investigate changes in BMD in RA patients receiving 3-year biological/targeted synthetic disease-modifying antirheumatic drugs (b/tsDMARD) or conventional synthetic DMARD (csDMARD). METHODS: Patients with RA were recruited from September 2014 until March 2019. Clinical characteristics, BMD and evidence of fragility fractures at enrolment were documented. Participants were treated according to the National Institute for Health and Care Excellence (NICE) guidelines over a 3-year obs...
#1Michele Russell-Westhead (Northumbria University)
#2Nicola O’Brien (Northumbria University)
Last. Fraser Birrell (Newcastle University)H-Index: 26
view all 6 authors...
Objectives: Group consultations are used for chronic conditions, such as inflammatory arthritis, but evidence of efficacy for treatment to target or achieving tight control is lacking. Our aim was to establish whether group consultation is a sustainable, co-designed routine care option and to explore factors supporting spread. Methods: The study used mixed methods, observational process/outcome data, plus qualitative exploration of enabling themes. It was set in two community hospitals, in 2008-...
Background: Methotrexate (MTX) at low dose is a key drug for rheumatoid arthritis (RA). MTX is widely used alone or combined with biologics or steroids. The aim was to study its effects on cytokine production using an in vitro model with synoviocytes interacting with peripheral blood mononuclear cells (PBMC) to reproduce the interactions in RA synovium. Methods: Activated-PBMC were co-cultured with RA synoviocytes during 48h. A dose-response of MTX was tested and different biotherapies (Inflixim...
#1James M. Gwinnutt (MAHSC: Manchester Academic Health Science Centre)H-Index: 2
#1James M. Gwinnutt (MAHSC: Manchester Academic Health Science Centre)H-Index: 2
Last. Rams coinvestigatorsH-Index: 1
view all 49 authors...
#1Guillermo Carvajal Alegria (French Institute of Health and Medical Research)H-Index: 5
#2Morgane MilinH-Index: 3
Last. Valérie Devauchelle-Pensec (French Institute of Health and Medical Research)H-Index: 32
view all 11 authors...
#1Kanta Kumar (University of Birmingham)H-Index: 11
#2Rebecca J. Stack (NTU: Nottingham Trent University)H-Index: 10
Last. Jo Adams (RMIT: RMIT University)H-Index: 14
view all 4 authors...
#1Josef S. Smolen (Medical University of Vienna)H-Index: 114
#2Ronald Pedersen (Pfizer)H-Index: 29
Last. Lisa Marshall (Pfizer)H-Index: 8
view all 5 authors...
1 CitationsSource
#1Xing Wang (SYSU: Sun Yat-sen University)
#2Sunny H. Wong (CUHK: The Chinese University of Hong Kong)H-Index: 26
Last. Siew C. Ng (CUHK: The Chinese University of Hong Kong)H-Index: 50
view all 12 authors...